Crinetics Pharmaceuticals, Inc. financial data

Symbol
CRNX on Nasdaq
Industry
Pharmaceutical Preparations
Location
10222 Barnes Canyon Road, Bldg. #2, San Diego, CA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 8, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.54K % +30.7%
Debt-to-equity 14.3 % +20.5%
Return On Equity -37 % +39.5%
Return On Assets -32.4 % +40.8%
Operating Margin 1.38M %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 80M shares
Common Stock, Shares, Outstanding 79.3M shares +45.1%
Entity Public Float 1B USD 0%
Common Stock, Value, Issued 881K USD
Weighted Average Number of Shares Outstanding, Basic 79M shares +45.6%
Weighted Average Number of Shares Outstanding, Diluted 79M shares +45.6%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 399K USD -59.6%
Research and Development Expense 201M USD +35.8%
General and Administrative Expense 78.2M USD +60.5%
Operating Income (Loss) -278M USD -44.8%
Nonoperating Income (Expense) 25.1M USD +210%
Net Income (Loss) Attributable to Parent -259M USD -40.6%
Earnings Per Share, Basic -3.77 USD/shares -10.9%
Earnings Per Share, Diluted -3.77 USD/shares -10.9%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 302M USD +664%
Cash, Cash Equivalents, and Short-term Investments 863M USD +226%
Other Assets, Current 1.51M USD -45.2%
Assets, Current 875M USD +207%
Property, Plant and Equipment, Net 12.2M USD +280%
Operating Lease, Right-of-Use Asset 45M USD +3492%
Other Assets, Noncurrent 2.2M USD +10.1%
Assets 936M USD +219%
Accounts Payable, Current 8.87M USD +83.1%
Liabilities, Current 54.4M USD +66.7%
Operating Lease, Liability, Noncurrent 45.9M USD +3051%
Other Liabilities, Noncurrent 202K USD
Liabilities 105M USD +168%
Common Stocks, Including Additional Paid in Capital 1.63B USD +105%
Accumulated Other Comprehensive Income (Loss), Net of Tax -190K USD +88.9%
Retained Earnings (Accumulated Deficit) -795M USD -48.2%
Stockholders' Equity Attributable to Parent 831M USD +227%
Liabilities and Equity 936M USD +219%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -52.9M USD -29.8%
Net Cash Provided by (Used in) Financing Activities 394M USD +81217%
Net Cash Provided by (Used in) Investing Activities 309K USD -99.4%
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 79.3M shares +45.1%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 341M USD +3902%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 303M USD +643%
Deferred Tax Assets, Valuation Allowance 185M USD +46.8%
Deferred Tax Assets, Gross 195M USD +54%
Operating Lease, Liability 53.3M USD +1979%
Payments to Acquire Property, Plant, and Equipment 1.33M USD +8225%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -257M USD -41.2%
Lessee, Operating Lease, Liability, to be Paid 83.3M USD +2898%
Property, Plant and Equipment, Gross 18.5M USD +136%
Operating Lease, Liability, Current 7.45M USD +571%
Lessee, Operating Lease, Liability, to be Paid, Year Two 7.47M USD +757%
Lessee, Operating Lease, Liability, to be Paid, Year One 3.86M USD +201%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 30M USD +13912%
Lessee, Operating Lease, Liability, to be Paid, Year Three 6.8M USD
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 6.95M USD +69%
Lessee, Operating Lease, Liability, to be Paid, Year Four 7M USD
Operating Lease, Payments 300K USD -66.7%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 55.1M USD +63.6%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%